These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
564 related articles for article (PubMed ID: 35758097)
21. Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Espejo-Cruz ML; González-Rubio S; Zamora-Olaya J; Amado-Torres V; Alejandre R; Sánchez-Frías M; Ciria R; De la Mata M; Rodríguez-Perálvarez M; Ferrín G Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884878 [TBL] [Abstract][Full Text] [Related]
22. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453 [TBL] [Abstract][Full Text] [Related]
23. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Giannopoulou L; Kasimir-Bauer S; Lianidou ES Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534 [TBL] [Abstract][Full Text] [Related]
24. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges. Seyhan AA Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063215 [TBL] [Abstract][Full Text] [Related]
25. Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. Teng PC; Agopian VG; Lin TY; You S; Zhu Y; Tseng HR; Yang JD J Gastroenterol Hepatol; 2022 Jul; 37(7):1179-1190. PubMed ID: 35543075 [TBL] [Abstract][Full Text] [Related]
26. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843 [TBL] [Abstract][Full Text] [Related]
27. Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma. Lehrich BM; Zhang J; Monga SP; Dhanasekaran R J Hepatol; 2024 Mar; 80(3):515-530. PubMed ID: 38104635 [TBL] [Abstract][Full Text] [Related]
28. The potential of liquid biopsy in the management of cancer patients. Markou A; Tzanikou E; Lianidou E Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850 [TBL] [Abstract][Full Text] [Related]
29. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564 [TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy: current technology and clinical applications. Nikanjam M; Kato S; Kurzrock R J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847 [TBL] [Abstract][Full Text] [Related]
31. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Kalinich M; Bhan I; Kwan TT; Miyamoto DT; Javaid S; LiCausi JA; Milner JD; Hong X; Goyal L; Sil S; Choz M; Ho U; Kapur R; Muzikansky A; Zhang H; Weitz DA; Sequist LV; Ryan DP; Chung RT; Zhu AX; Isselbacher KJ; Ting DT; Toner M; Maheswaran S; Haber DA Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1123-1128. PubMed ID: 28096363 [TBL] [Abstract][Full Text] [Related]
33. Liquid biopsies for hepatocellular carcinoma. Su YH; Kim AK; Jain S Transl Res; 2018 Nov; 201():84-97. PubMed ID: 30056068 [TBL] [Abstract][Full Text] [Related]
34. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Chen VL; Xu D; Wicha MS; Lok AS; Parikh ND Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2879-2902.e9. PubMed ID: 32289533 [TBL] [Abstract][Full Text] [Related]
35. A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance. Nicolazzo C; Gazzaniga P Methods Mol Biol; 2022; 2535():93-104. PubMed ID: 35867225 [TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691 [TBL] [Abstract][Full Text] [Related]
37. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963 [TBL] [Abstract][Full Text] [Related]
38. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management. Fici P Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422 [TBL] [Abstract][Full Text] [Related]
39. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267 [TBL] [Abstract][Full Text] [Related]
40. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Dhayat SA; Yang Z J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]